Press Releases April 23, 2026 08:30 AM

GCM Grosvenor to Announce First Quarter 2026 Financial Results and Host Investor Conference Call on May 7, 2026

GCM Grosvenor to Report Q1 2026 Financial Results and Host Investor Call on May 7, 2026

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
GCMG

GCM Grosvenor, a global alternative asset management firm, announced it will release its first quarter 2026 financial results on May 7, 2026, followed by a webcast and conference call to discuss the financials and provide business updates.

GCM Grosvenor to Announce First Quarter 2026 Financial Results and Host Investor Conference Call on May 7, 2026
GCMG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • GCM Grosvenor manages approximately $91 billion in assets across alternative investments including private equity, infrastructure, real estate, credit, and absolute return strategies.
  • The company has a global client base and workforce, with headquarters in Chicago and offices worldwide, indicating diversified geographic presence.
  • The upcoming earnings release and corresponding webcast offer transparency to investors and an opportunity to gain insights into the firm's recent performance and strategy.

CHICAGO, April 23, 2026 (GLOBE NEWSWIRE) -- GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, announced today that it will release its results for the first quarter 2026 on Thursday, May 7, 2026.

Management will host a webcast and conference call on May 7, 2026, at 10:00 a.m. ET to discuss the results and provide a business update. The conference call will be available via public webcast through the Public Shareholders section of GCM Grosvenor’s website at
www.gcmgrosvenor.com/public-shareholders and a replay will be available on the website soon after the call’s completion for at least seven (7) days.

To register for the call, visit www.gcmgrosvenor.com/public-shareholders.

About GCM Grosvenor

GCM Grosvenor (Nasdaq: GCMG) is a global alternative asset management solutions provider with approximately $91 billion in assets under management across private equity, infrastructure, real estate, credit, and absolute return investment strategies. The firm has specialized in alternatives for more than 50 years and is dedicated to delivering value for clients by leveraging its cross-asset class and flexible investment platform. 

GCM Grosvenor’s experienced team of approximately 550 professionals serves a global client base of institutional and individual investors. The firm is headquartered in Chicago, with offices in New York, Toronto, London, Frankfurt, Tokyo, Hong Kong, Seoul and Sydney. For more information, visit: gcmgrosvenor.com.

Source: GCM Grosvenor

Public Shareholders Contact
Stacie Selinger
sselinger@gcmlp.com
312-506-6583

Media Contact
Abigail Ruck
H/Advisors Abernathy
abigail.ruck@h-advisors.global
212-371-5999


Risks

  • Financial results may reveal weaker-than-expected performance impacting investor sentiment and stock price.
  • Market volatility and economic conditions could affect the alternative asset management sector's performance and GCM Grosvenor's asset valuations.
  • Uncertainties related to global macroeconomic factors and regulatory environment might influence the firm's future growth and profitability.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026